{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:08:08Z","timestamp":1788433688755,"version":"build-2803163510"},"reference-count":14,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,19]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The MCL35 gene expression assay encompasses key risk features and stratified older patients with mantle cell lymphoma (MCL) using routine biopsies. In the SHINE trial, high-risk patients had poor outcomes despite adding ibrutinib to bendamustine-rituximab, highlighting an urgent need for novel strategies in high-risk MCL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024026003","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T19:20:09Z","timestamp":1742325609000},"page":"3052-3056","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and <i>TP53<\/i> mutation status"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"first","affiliation":[{"name":"1H. Lee Moffitt Cancer Centre and Research Institute, Tampa, FL"},{"name":"2Morsani College of Medicine, University of South Florida, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7202-9425","authenticated-orcid":false,"given":"Srimathi","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"3Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Hodkinson","sequence":"additional","affiliation":[{"name":"3Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Deshpande","sequence":"additional","affiliation":[{"name":"4Johnson & Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Henninger","sequence":"additional","affiliation":[{"name":"4Johnson & Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-0103","authenticated-orcid":false,"given":"Merrill","family":"Boyle","sequence":"additional","affiliation":[{"name":"5BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[{"name":"6Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-5249","authenticated-orcid":false,"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"7Department of Medicine III, Ludwig Maximilian University Hospital, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"5BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada"},{"name":"8Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2025061911212408500_bib1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022\u2014a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2025061911212408500_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hon.3149","article-title":"Mantle cell lymphoma\u2014update on molecular biology, prognostication and treatment approaches","volume":"41","author":"Silkenstedt","year":"2023","journal-title":"Hem Oncol"},{"issue":"15","key":"2025061911212408500_bib3","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","article-title":"New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025061911212408500_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"issue":"10","key":"2025061911212408500_bib5","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/s41375-022-01658-2","article-title":"Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial","volume":"36","author":"Freeman","year":"2022","journal-title":"Leukemia"},{"issue":"26","key":"2025061911212408500_bib6","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"2025061911212408500_bib7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12308-020-00418-4","article-title":"Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma","volume":"13","author":"Ramsower","year":"2020","journal-title":"J Hematop"},{"issue":"5","key":"2025061911212408500_bib8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025061911212408500_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00428-020-02750-7","article-title":"Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11","volume":"477","author":"Croci","year":"2020","journal-title":"Virchows Arch"},{"issue":"10441","key":"2025061911212408500_bib10","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"2025061911212408500_bib11","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1080\/10428194.2023.2215888","article-title":"Cost-effectiveness of brexucabtagene autoleucel for relapsed\/refractory mantle cell lymphoma","volume":"64","author":"Marchetti","year":"2023","journal-title":"Leuk Lymph"},{"issue":"5","key":"2025061911212408500_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"issue":"42","key":"2025061911212408500_bib13","first-page":"1","article-title":"New directions for mantle cell lymphoma in 2022","volume":"42","author":"Kumar","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"2025061911212408500_bib14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024026003\/2380221\/blood_bld-2024-026003-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024026003\/2380221\/blood_bld-2024-026003-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T15:21:31Z","timestamp":1750346491000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/25\/3052\/536114\/Prognostic-biomarkers-in-MCL-insights-from-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":14,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2025,6,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026003","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,19]]},"published":{"date-parts":[[2025,6,19]]}}}